BioVie Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Selling, General & Admin	8.51	8.57	8.85	11.55	9.77
Research & Development	13.96	9.27	23.1	33.3	17.26
Amortization of Goodwill & Intangibles	0.18	0.23	0.23	0.23	0.23
Operating Expenses	22.65	18.07	32.18	45.08	27.25
Operating Income	-22.65	-18.07	-32.18	-45.08	-27.25
Interest Expense	-0.02	-0.33	-2.89	-4.3	-2.16
Interest & Investment Income	0.6	0.85	1.14	0.56	0.04
Other Non Operating Income (Expenses)	-	0	1.82	-1.44	3.29
EBT Excluding Unusual Items	-22.07	-17.54	-32.12	-50.26	-26.08
Pretax Income	-22.07	-17.54	-32.12	-50.26	-26.08
Net Income	-22.07	-17.54	-32.12	-50.26	-26.08
Preferred Dividends & Other Adjustments	0.04	0.37	0.89	-	-
Net Income to Common	-22.12	-17.91	-33.01	-50.26	-26.08
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	7	1	0	0	0
Shares Outstanding (Diluted)	7	1	0	0	0
Shares Change	390.46%	226.96%	39.10%	31.71%	98.84%
EPS (Basic)	-3.05	-12.12	-73.05	-154.71	-105.77
EPS (Diluted)	-3.05	-12.12	-73.05	-154.71	-106.00
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
EBITDA	-22.47	-17.84	-31.95	-44.85	-27.02
D&A For EBITDA	0.18	0.23	0.23	0.23	0.23
EBIT	-22.65	-18.07	-32.18	-45.08	-27.25

SEC Filings: 10-K · 10-Q